Recent News

• 02.16.2025 - ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
• 02.16.2025 - ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
• 02.03.2025 - ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
• 02.03.2025 - ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
• 01.13.2025 - ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
• 01.13.2025 - ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

Recent Filings

• 02.14.2025 - S-1MEF Registration adding securities to prior Form S-1 registration [Rule 462(b)]
• 02.14.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 02.14.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 02.14.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 02.13.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 02.07.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 02.06.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 01.21.2025 - 8-K Current report
• 01.21.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 01.15.2025 - S-4/A Registration of securities, business combinations